ImmunityBio Sees Unusually High Options Volume (NASDAQ:IBRX)

ImmunityBio, Inc. (NASDAQ:IBRX) was the target of some unusual options trading on Thursday. Stock investors acquired 8,015 call options on the company. This represents an increase of 36% compared to the average daily volume of 5,894 call options.

Hedge Funds Weigh In On ImmunityBio

Several hedge funds and other institutional investors have recently modified their holdings of IBRX. State Street Corp increased its stake in shares of ImmunityBio by 10.1% in the third quarter. State Street Corp now owns 8,654,460 shares of the company’s stock valued at $32,195,000 after purchasing an additional 790,408 shares during the period. Barclays PLC lifted its holdings in ImmunityBio by 127.4% in the third quarter. Barclays PLC now owns 361,036 shares of the company’s stock worth $1,344,000 after purchasing an additional 202,248 shares during the period. HighTower Advisors LLC bought a new position in ImmunityBio in the 3rd quarter valued at about $136,000. Mirae Asset Global Investments Co. Ltd. increased its stake in ImmunityBio by 22.0% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 25,192 shares of the company’s stock valued at $99,000 after buying an additional 4,545 shares during the period. Finally, Private Advisor Group LLC raised its position in shares of ImmunityBio by 727.7% during the 2nd quarter. Private Advisor Group LLC now owns 86,907 shares of the company’s stock worth $549,000 after buying an additional 76,407 shares in the last quarter. Institutional investors and hedge funds own 8.58% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently issued reports on IBRX. D. Boral Capital reissued a “buy” rating and set a $30.00 price target on shares of ImmunityBio in a research report on Thursday. EF Hutton Acquisition Co. I upgraded shares of ImmunityBio to a “strong-buy” rating in a research report on Wednesday, October 23rd. Finally, BTIG Research began coverage on shares of ImmunityBio in a research report on Friday, January 10th. They set a “buy” rating and a $6.00 price objective for the company.

ImmunityBio Stock Performance

Shares of IBRX opened at $2.94 on Friday. ImmunityBio has a 12 month low of $2.28 and a 12 month high of $10.53. The stock has a fifty day moving average price of $3.69 and a 200 day moving average price of $4.23.

About ImmunityBio

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.